New drug trial aims for completely clear skin in psoriasis patients

NCT ID NCT03536884

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

Summary

This study tested if a new drug called bimekizumab works better than an existing drug, secukinumab, for adults with moderate to severe plaque psoriasis. It involved 743 participants and measured how clear their skin became over 48 weeks. The main goal was to see if bimekizumab could lead to 100% skin clearance more effectively.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

PS0015 3

Carlton, Australia
PS0015 6

Kogarah, Australia
PS0015 7

Hectorville, Australia
PS0015 9

Woolloongabba, Australia
Ps0015 11

Parkville, Australia
Ps0015 153

Toulouse, France
Ps0015 204

Witten, Germany
Ps0015 211

Hamburg, Germany
Ps0015 213

Mahlow, Germany
Ps0015 215

Lübeck, Germany
Ps0015 219

Münster, Germany
Ps0015 222

Tübingen, Germany
Ps0015 223

Augsburg, Germany
Ps0015 234

München, Germany
Ps0015 236

Neu-Ulm, Germany
Ps0015 237

Berlin, Germany
Ps0015 238

Mainz, Germany
Ps0015 263

Breda, Netherlands
Ps0015 265

Amsterdam, Netherlands
Ps0015 352

Gdansk, Poland
Ps0015 355

Bialystok, Poland
Ps0015 361

Bialystok, Poland
Ps0015 366

Katowice, Poland
Ps0015 368

Wroclaw, Poland
Ps0015 369

Bialystok, Poland
Ps0015 372

Lodz, Poland
Ps0015 375

Wroclaw, Poland
Ps0015 376

Krakow, Poland
Ps0015 377

Ostrowiec Świętokrzyski, Poland
Ps0015 378

Katowice, Poland
Ps0015 379

Krakow, Poland
Ps0015 450

Barcelona, Spain
Ps0015 451

Madrid, Spain
Ps0015 454

Madrid, Spain
Ps0015 455

Alicante, Spain
Ps0015 456

Madrid, Spain
Ps0015 457

Sant Joan Despí, Spain
Ps0015 50

Brussels, Belgium
Ps0015 52

Liège, Belgium
Ps0015 54

Brussels, Belgium
Ps0015 555

Salford, United Kingdom
Ps0015 559

Newcastle upon Tyne, United Kingdom
Ps0015 657

Waterloo, Canada
Ps0015 661

Peterborough, Canada
Ps0015 663

Mississauga, Canada
Ps0015 671

Hamilton, Canada
Ps0015 673

Halifax, Canada
Ps0015 677

Toronto, Canada
Ps0015 678

Richmond Hill, Canada
Ps0015 760

Kayseri, Turkey (Türkiye)
Ps0015 762

Istanbul, Turkey (Türkiye)
Ps0015 763

Gaziantep, Turkey (Türkiye)
Ps0015 900

West Des Moines, Iowa, 50265, United States
Ps0015 901

Portsmouth, New Hampshire, 03801, United States
Ps0015 903

Ocala, Florida, 34470, United States
Ps0015 915

Clayton, Missouri, 63105, United States
Ps0015 920

Portland, Oregon, 97210, United States
Ps0015 921

Ormond Beach, Florida, 32174, United States
Ps0015 924

Houston, Texas, 77004, United States
Ps0015 929

Portland, Oregon, 97223, United States
Ps0015 936

Tampa, Florida, 33613, United States
Ps0015 939

Danbury, Connecticut, 06810, United States
Ps0015 944

New Orleans, Louisiana, 70115, United States
Ps0015 953

St Louis, Missouri, 63141, United States
Ps0015 954

Skokie, Illinois, 60077, United States
Ps0015 965

Kew Gardens, New York, 11415, United States
Ps0015 966

Sandy Springs, Georgia, 30328, United States
Ps0015 969

High Point, North Carolina, 27262, United States
Ps0015 970

West Palm Beach, Florida, 33409, United States
Ps0015 971

Wilmington, North Carolina, 28405, United States
Ps0015 972

West Dundee, Illinois, 60118, United States
Ps0015 975

Santa Ana, California, 92701, United States
Ps0015 976

Tampa, Florida, 33614, United States
Ps0015 977

Pembroke Pines, Florida, 33028, United States
Ps0015 978

Pflugerville, Texas, 78660, United States
Ps0015 979

Dallas, Texas, 75246, United States
Ps0015 980

Bexley, Ohio, 43209, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC PLAQUE PSORIASIS MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS